Siloton has secured £860,000 to advance the commercial rollout of its eye imaging chip technology, which is designed to enhance the diagnosis and monitoring of treatable retinal diseases. The company’s technology condenses the equipment typically found in doctors’ offices into a single chip smaller than a £1 coin, allowing patients to manage their conditions from the comfort of home.
The funding round includes contributions from Evenlode Impact Investments and members of the South East Angels and the Francis Crick Institute, along with non-dilutive support from an Innovate U.K. Biomedical Catalyst grant, bringing the company’s total funding to £1.7 million.
Siloton CEO Dr. Alasdair Prince said in a statement that this investment will facilitate the company’s transition from research and development to product commercialization. The fresh capital will help develop Siloton’s Akepa optical coherence tomography chip technology. The company aims to launch a researcher-focused version of the product 2025.
